Last reviewed · How we verify

Biguanides, thiazolidinediones

University of Pittsburgh · Phase 3 active Small molecule

Biguanides, thiazolidinediones is a Antidiabetic combination therapy Small molecule drug developed by University of Pittsburgh. It is currently in Phase 3 development for Type 2 diabetes mellitus.

This combination of biguanides and thiazolidinediones improves insulin sensitivity and reduces hepatic glucose production through complementary mechanisms in type 2 diabetes management.

This combination of biguanides and thiazolidinediones improves insulin sensitivity and reduces hepatic glucose production through complementary mechanisms in type 2 diabetes management. Used for Type 2 diabetes mellitus.

At a glance

Generic nameBiguanides, thiazolidinediones
SponsorUniversity of Pittsburgh
Drug classAntidiabetic combination therapy
TargetPPAR-γ (thiazolidinedione component); mitochondrial respiratory chain complex I (biguanide component)
ModalitySmall molecule
Therapeutic areaDiabetes
PhasePhase 3

Mechanism of action

Biguanides (e.g., metformin) decrease hepatic glucose production and improve peripheral insulin sensitivity, while thiazolidinediones enhance insulin sensitivity in muscle and adipose tissue by activating PPAR-γ. Together, they address multiple pathophysiological defects in type 2 diabetes through synergistic glucose-lowering effects.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Biguanides, thiazolidinediones

What is Biguanides, thiazolidinediones?

Biguanides, thiazolidinediones is a Antidiabetic combination therapy drug developed by University of Pittsburgh, indicated for Type 2 diabetes mellitus.

How does Biguanides, thiazolidinediones work?

This combination of biguanides and thiazolidinediones improves insulin sensitivity and reduces hepatic glucose production through complementary mechanisms in type 2 diabetes management.

What is Biguanides, thiazolidinediones used for?

Biguanides, thiazolidinediones is indicated for Type 2 diabetes mellitus.

Who makes Biguanides, thiazolidinediones?

Biguanides, thiazolidinediones is developed by University of Pittsburgh (see full University of Pittsburgh pipeline at /company/university-of-pittsburgh).

What drug class is Biguanides, thiazolidinediones in?

Biguanides, thiazolidinediones belongs to the Antidiabetic combination therapy class. See all Antidiabetic combination therapy drugs at /class/antidiabetic-combination-therapy.

What development phase is Biguanides, thiazolidinediones in?

Biguanides, thiazolidinediones is in Phase 3.

What are the side effects of Biguanides, thiazolidinediones?

Common side effects of Biguanides, thiazolidinediones include Hypoglycemia, Weight gain, Fluid retention / edema, Gastrointestinal disturbance (nausea, diarrhea), Lactic acidosis risk (biguanide component), Heart failure exacerbation.

What does Biguanides, thiazolidinediones target?

Biguanides, thiazolidinediones targets PPAR-γ (thiazolidinedione component); mitochondrial respiratory chain complex I (biguanide component) and is a Antidiabetic combination therapy.

Related